REG - Nuformix PLC - Exercise of Warrants

NuformixAnnouncement

14/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250414:nRSN8610Ea&default-theme=true

RNS Number : 8610E  Nuformix PLC  14 April 2025

14 April 2025

 

Nuformix plc

("Nuformix" or the "Company")

 

Exercise of Warrants

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that it
has received a notice of exercise of broker warrants to subscribe for a total
of 26,400,000 new ordinary shares of 0.05 pence each in the capital of the
Company ("Ordinary Shares") (the "New Ordinary Shares"). The New Ordinary
Shares are being issued at a price of 0.05 pence per share, for a total
consideration to the Company of £13,200.

 

The New Ordinary Shares will rank pari passu with the existing Ordinary Shares
and application has been made for the New Ordinary Shares to be admitted to
the Official List of the FCA and to trading on the Main Market of the London
Stock Exchange ("Admission").  It is expected that Admission will become
effective and dealings in the New Ordinary Shares will commence at 8.00 a.m.
on 18 April 2025.

 

Total Voting Rights

 

Upon Admission, the Company's issued share capital will consist of
1,695,709,368 Ordinary Shares with one voting right each. The Company does not
hold any Ordinary Shares in treasury. Therefore, the total number of voting
rights in the Company will be 1,695,709,368.  With effect from Admission,
this figure may be used by shareholders in the Company as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPKNBBKBKBBQD